Michael Hay is an accomplished BioPharma Business Intelligence executive with over 25 years of experience growing, integrating, and transacting data and services companies. He helped build the Biomedtracker product at Sagient Research, supported the sale to Informa in 2012, and subsequently managed various parts of the Informa Pharma Intelligence business with P&L responsibility ranging from $20m–$150m before helping sell the unit to Warburg as Citeline in 2022, where he stayed on as General Manager of Strategic Intelligence at Norstella. Following Norstella, Michael Co-Founded QLS Technologies with MIT’s Andrew Lo. A recognized thought leader, Michael is the lead author of the landmark study "Clinical Development Success Rates for Investigational Drugs" published in Nature Biotechnology in 2014, which remains a widely cited benchmark for drug development probabilities of success and has informed predictive analytics tools including Biomedtracker's Likelihood of Approval model. Throughout his career, he has consulted for leading pharmaceutical companies and investment firms, playing a pivotal role in shaping healthcare intelligence platforms and supporting critical investment and business decisions in the life sciences sector.

A seasoned healthcare journalist and editor, Surani has spent well over a decade covering the biopharma sector for an industry and an investor audience. A Sydney native, her investigative journalism career kicked-off in London in 2010 where she covered clinical trials & business deals for BioPharm Insight, a subscription-based investigative news service launched by the Financial Times Group. After rising to European Editor in 2015, she moved to New York in 2016 to lead the North America desk, under new owners GlobalData. In 2019, she joined financial newswire Reorg, where she focused her investigative coverage on multibillion dollar M&A deals in the biopharma space. She is now a freelance journalist, consultant writer & podcast producer based in Madrid. She launched The Vax Files podcast in 2021 & the Raising Biotech podcast in 2023. She has a Bachelor of Medical Science & Master of Health Communications from Sydney University.

Mark Crowell, RTTP, is President and Co-Founder of Arkane Innovation, an international advisory services firm (based in Ireland, the UK and the US) focused on entrepreneurship, innovation ecosystems and strategy, accelerator programs, research commercialization and spinouts, and economic development initiatives. He is also Executive Entrepreneur in Residence for the Eshelman Institute for Innovation (EII) at the UNC Eshelman School of Pharmacy. Mark is a Senior Innovation Advisor to the World Bank and consults with the AAAS, the San Diego Biomedical Research Institute, the Arkansas Research Alliance, and others. Mark’s 30+ years of experience in academic innovation and translational partnerships include serving as Vice President for Innovation and Economic Development at the King Abdullah University of Science and Technology (KAUST) in Saudi Arabia; founding Executive Director of UVa Innovation at the University of Virginia; and chief technology transfer and business development officer at The Scripps Research Institute, the University of North Carolina at Chapel Hill, NC State University, and Duke University.
‍
Mark was 2005 President of the Association of University Technology Managers (AUTM), a former Chair of BIO's Technology Transfer Committee (2009-2014), and a former member of the National Advisory Council of the Federal Laboratory Consortium (FLC).  In 2013, Mark received the Bayh-Dole Award from AUTM “in recognition of his lifetime contributions to advancing academic innovations.” In 2011, he was invited by the White House to attend President Barack Obama’s signing ceremony for the America Invents Act.